Genomic Health Inc. (GHDX) Receives $30.88 Average PT from Brokerages
Shares of Genomic Health Inc. (NASDAQ:GHDX) have been given an average recommendation of “Hold” by the ten brokerages that are presently covering the company. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $30.88.
GHDX has been the topic of a number of analyst reports. Zacks Investment Research raised Genomic Health from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research note on Tuesday, October 4th. Jefferies Group increased their price objective on Genomic Health from $25.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, August 17th. Canaccord Genuity reaffirmed a “buy” rating and set a $38.00 price objective on shares of Genomic Health in a research note on Friday, August 5th. Leerink Swann reaffirmed a “buy” rating on shares of Genomic Health in a research note on Tuesday, June 21st. Finally, Bank of America Corp. set a $28.00 target price on Genomic Health and gave the stock a “sell” rating in a research report on Wednesday, August 3rd.
In other news, COO G Bradley Cole sold 8,290 shares of the stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $30.59, for a total value of $253,591.10. Following the completion of the sale, the chief operating officer now owns 39,426 shares in the company, valued at $1,206,041.34. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider James J. Vaughn sold 3,000 shares of the stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $28.74, for a total value of $86,220.00. The disclosure for this sale can be found here. 47.00% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of GHDX. American International Group Inc. raised its stake in Genomic Health by 3.2% in the second quarter. American International Group Inc. now owns 10,753 shares of the company’s stock worth $278,000 after buying an additional 334 shares during the period. Nationwide Fund Advisors raised its stake in Genomic Health by 3.0% in the second quarter. Nationwide Fund Advisors now owns 11,932 shares of the company’s stock worth $309,000 after buying an additional 351 shares during the period. Kimelman & Baird LLC raised its stake in Genomic Health by 2.3% in the first quarter. Kimelman & Baird LLC now owns 21,940 shares of the company’s stock worth $543,000 after buying an additional 500 shares during the period. ProShare Advisors LLC raised its stake in Genomic Health by 2.2% in the second quarter. ProShare Advisors LLC now owns 26,858 shares of the company’s stock worth $695,000 after buying an additional 591 shares during the period. Finally, Swiss National Bank raised its stake in Genomic Health by 2.3% in the second quarter. Swiss National Bank now owns 31,200 shares of the company’s stock worth $808,000 after buying an additional 700 shares during the period. Institutional investors and hedge funds own 88.92% of the company’s stock.
Genomic Health (NASDAQ:GHDX) opened at 29.30 on Wednesday. Genomic Health has a 52-week low of $20.05 and a 52-week high of $35.79. The firm has a 50-day moving average price of $28.36 and a 200 day moving average price of $27.34. The firm’s market capitalization is $977.04 million.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.18) EPS for the quarter, meeting analysts’ consensus estimates of ($0.18). The business had revenue of $81.97 million for the quarter, compared to analyst estimates of $81.27 million. Genomic Health had a negative return on equity of 21.02% and a negative net margin of 8.84%. The business’s revenue for the quarter was up 16.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.29) earnings per share. Analysts forecast that Genomic Health will post ($0.47) EPS for the current year.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.